193 related articles for article (PubMed ID: 37905641)
1. Association of Torsade de Pointes and QT Prolongation With Antifungal Triazoles: Analysis Using a Pharmacovigilance Database.
Ohyama K; Akiyama S; Iida M; Hori Y
In Vivo; 2023; 37(6):2719-2725. PubMed ID: 37905641
[TBL] [Abstract][Full Text] [Related]
2. Torsade de Pointes/QT Prolongation Associated with Antifungal Triazoles: A Pharmacovigilance Study Based on the U.S. FDA Adverse Event Reporting System（FAERS）.
Yu Z; Liao X
J Pharm Pharm Sci; 2022; 25():237-243. PubMed ID: 35790147
[TBL] [Abstract][Full Text] [Related]
3. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Teng C; Walter EA; Gaspar DKS; Obodozie-Ofoegbu OO; Frei CR
Int J Med Sci; 2019; 16(7):1018-1022. PubMed ID: 31341415
[No Abstract] [Full Text] [Related]
4. A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
Diaby V; Almutairi RD; Chen Z; Moussa RK; Berthe A
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):159-168. PubMed ID: 33186061
[No Abstract] [Full Text] [Related]
5. A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system.
Yan Y; Wu B; Wang L
Expert Opin Drug Saf; 2024 Mar; ():1-8. PubMed ID: 38482864
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W
Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046
[TBL] [Abstract][Full Text] [Related]
7. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
8. Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System.
Shao H; Shi D; Dai Y
Br J Clin Pharmacol; 2023 Apr; 89(4):1386-1392. PubMed ID: 36346345
[TBL] [Abstract][Full Text] [Related]
9. OTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy.
Elbey MA; Cil H; Onturk E; Islamoglu Y
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):100-2. PubMed ID: 22338554
[TBL] [Abstract][Full Text] [Related]
10. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
Li D; Chai S; Wang H; Dong J; Qin C; Du D; Wang Y; Du Q; Liu S
Front Pharmacol; 2023; 14():1259611. PubMed ID: 38186652
[No Abstract] [Full Text] [Related]
12. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
Saint-Gerons DM; Tabarés-Seisdedos R
Eur J Clin Pharmacol; 2021 Oct; 77(10):1513-1521. PubMed ID: 33938974
[TBL] [Abstract][Full Text] [Related]
13. Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data.
Sessler NE; Walker E; Chickballapur H; Kacholakalayil J; Coplan PM
Postgrad Med; 2017 Jan; 129(1):62-68. PubMed ID: 27977317
[TBL] [Abstract][Full Text] [Related]
14. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
Meyer-Massetti C; Cheng CM; Sharpe BA; Meier CR; Guglielmo BJ
J Hosp Med; 2010 Apr; 5(4):E8-16. PubMed ID: 20394022
[TBL] [Abstract][Full Text] [Related]
15. Drug-Induced QT Prolongation and Torsade de Pointes in Spontaneous Adverse Event Reporting: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database (2004-2021).
Uchikawa M; Hashiguchi M; Shiga T
Drugs Real World Outcomes; 2022 Dec; 9(4):551-559. PubMed ID: 35994235
[TBL] [Abstract][Full Text] [Related]
16. QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review.
Khokhar B; Chiang B; Iglay K; Reynolds K; Rodriguez-Ormaza N; Spalding W; Freedland E
Clin Lung Cancer; 2024 Jun; 25(4):285-318. PubMed ID: 38553324
[TBL] [Abstract][Full Text] [Related]
17. Cases of drug-induced Torsade de Pointes: a review of Belgian cases in the EudraVigilance database.
Vandael E; Vandenberk B; Vandenberghe J; Willems R; Foulon V
Acta Clin Belg; 2017 Dec; 72(6):385-390. PubMed ID: 28335691
[TBL] [Abstract][Full Text] [Related]
18. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Sarayani A; Cicali B; Henriksen CH; Brown JD
Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
[TBL] [Abstract][Full Text] [Related]
19. Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study.
Salem JE; Bretagne M; Lebrun-Vignes B; Waintraub X; Gandjbakhch E; Hidden-Lucet F; Gougis P; Bachelot A; Funck-Brentano C;
Arch Cardiovasc Dis; 2019 Nov; 112(11):699-712. PubMed ID: 31477476
[TBL] [Abstract][Full Text] [Related]
20. Psychotherapeutic drug-induced life-threatening arrhythmias: A retrospective analysis using the Japanese adverse drug event report database.
Yokohara S; Hashiguchi M; Shiga T
J Arrhythm; 2023 Dec; 39(6):928-936. PubMed ID: 38045460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
